Corrigendum to "Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin" [Cytokine 40 (2007) 201-206] (DOI:10.1016/j.cyto.2007.09.011);Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin

Cytokine

Volumn 40, Issue 3, 2007, Pages 201-206

  Hu, Wen Lan ^a   Qian, Shu Bing ^a   Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Atherosclerosis; C reactive protein; Inflammation; Resistin; Simvastatin

Indexed keywords

C REACTIVE PROTEIN; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; RESISTIN; SIMVASTATIN;

ARTICLE; CENTRIFUGATION; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; INCUBATION TIME; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RISK FACTOR;

RODENTIA;

EID: 36749013639     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.03.011     Document Type: Erratum

References (34)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl Med J 340 (1999) 115-126
2. Shah P.K. Circulating markers of inflammation for vascular risk prediction: are they ready for prime time?. Circulation 101 (2000) 1758-1759
3. Plutzky J. Inflammatory pathway in atherosclerosis and acute coronary syndromes. Am J Cardiol 88 (2001) 5K-10K
4. Steppan C.M., Bailey S.T., Bhat S., et al. The hormone resistin links obesity to diabetes. Nature 409 6818 (2001) 307-312
5. Mu H., Ohashi R., Yan S., et al. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 70 1 (2006) 146-157
6. Rae C., and Graham A. Human resistin promotes macrophage lipid accumulation. Diabetologia 49 5 (2006) 1112-1114
7. Burnett M.S., Lee C.W., Kinnaird T.D., et al. The potential role of resistin in atherogenesis. Atherosclerosis 182 2 (2005) 241-248
8. Jung H.S., Park K.H., Cho Y.M., et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 69 1 (2006) 76-85
9. Reilly M.P., Lehrke M., Wolfe M.L., et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111 7 (2005) 932-939
10. Lu S.C., Shieh W.Y., Chen C.Y., et al. Lipopolysaccharide increases resistin gene expression in vivo and in vitro. FEBS Lett 530 1-3 (2002) 158-162
11. Kaser S., Kaser A., and Sandhofer A. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 309 2 (2003) 286-290
12. Michael L., Muredach P., Segan C., et al. An inflammatory cascade leading to hyper-resistinemia in Humans. PLoS Med 1 2 (2004) e45-e53
13. Veillard N.R., and Mach F. Statins: the new aspirin?. Cell Mol Life Sci 59 (2002) 1771-1786
14. Rosenson R.S., and Tangney C.C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 279 (1998) 1643-1650
15. Kita T., Brown M.S., and Goldstein J.L. Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J Clin Invest 66 (1980) 1094-1100
16. Bokarewa M., Nagaev I., Dahlberg L., et al. Resistin, an adipokine with potent proinflammatory properties. J Immunol 174 9 (2005) 5789-5795
17. Silswal N., Singh A.K., Aruna B., et al. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappa B-dependent pathway. Biochem Biophys Res Commun 334 4 (2005) 1092-1101
18. Verma S., Li S.H., Wang C.H., et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 108 (2003) 736-740
19. Daiji K., Koji M., Norihiko T., et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 314 2 (2004) 415-419
20. Calabro P., Samudio I., Willerson J.T., et al. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 110 21 (2004) 3335-3340
21. Ohmori R., Momiyama Y., Kato R., et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 46 2 (2005) 379-380
22. Lubos E., Messow C.M., Schnabel R., et al. Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis (2006) [Epub ahead of print]
23. Li J.-J., and Fang C.-H. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular disease. Med Hypotheses 62 (2004) 499-506
24. Jialal I., and Devaraj S. Inflammation and atherosclerosis: the value of the high sensitive C-reactive protein assay as a marker. Am J Clin Pathol 116 (2001) S108-S115
25. Robey F.A., Ohura K., Futaki S., et al. Proteolysis of human C-reactive protein produces peptides with potent immunomodulating activity. J Biol Chem 262 (1987) 7053-7057
26. Devaraj S., Xu D.Y., and Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107 (2003) 398-404
27. Venugopal S.K., Devaraj S., Yuhanna I., et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106 (2002) 1439-1441
28. Venugopal S.K., Devaraj S., and Jialal I. C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 108 (2003) 1676-1678
29. Wang C.H., Li S.H., Weisel R.D., et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 107 (2003) 1783-1790
30. Haverkate F., Thompson S.G., Pyke S.D., et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349 (1997) 462-466
31. Biasucci L.M., Liuzzo G., Grillo R.L., et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 99 (1999) 855-860
32. Ridker P.M., Rifai N., Pfeffer M.A., et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein: the cholesterol and recurrent events (CARE) investigators. Circulation 100 (1999) 230-235
33. Ichida Y., Hasegawa G., Fukui M., et al. Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes. Pharmacology 76 1 (2005) 34-39
34. Schonbeck U., and Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?. Circulation 109 21 Suppl. 1 (2004) II18-II26